Entity

Time filter

Source Type

Isparta, Turkey

Cosar C.B.,Acibadem University | Sener A.B.,Eye Clinic
European Journal of Ophthalmology | Year: 2014

Purpose: To investigate refractive and visual outcomes and complications of the Supracor procedure to treat presbyopia. Methods: A total of 123 eyes from 68 presbyopic patients with hyperopia were enrolled in this prospective, nonrandomized, clinical trial. The Supracor procedure was performed using the Technolas excimer laser 217P (Technolas Perfect Vision GmbH). Follow-up eye examinations were performed at postoperative day 1, month 1, and month 6. Results: All 123 surgeries were uneventful. At 6 months postoperatively, uncorrected distance visual acuity was 20/20 or better in 27 (22.0%) eyes and 20/25 or better in 45 (36.6%) eyes. At 6 months postoperatively, 35 (28.5%) eyes lost 1 line and 13 (10.6%) eyes lost 2 lines of corrected distance visual acuity (CDVA). At 6 months postoperatively, uncorrected near visual acuity was 20/20 or better in 95 (77.2%) eyes and 20/25 or better in 110 (89.4%) eyes. At 6 months postoperatively, 6 (4.9%) eyes lost 1 line of corrected near visual acuity. Conclusions: The Supracor presbyopia procedure showed good near visual acuity outcomes over 6 months follow-up but loss of CDVA occurred in 39.1% of eyes. © 2013 Wichtig Editore. Source


Russo A.,University of Brescia | Costagliola C.,University of Molise | Delcassi L.,University of Brescia | Romano M.R.,Eye Clinic | Semeraro F.,University of Brescia
British Journal of Ophthalmology | Year: 2013

Aims: To evaluate whether ketorolac eyedrops and ranibizumab intravitreal injections would provide additional benefit over ranibizumab alone in the treatment of choroidal neovascularisation (CNV). Methods: This was a pilot study of eyes with new-onset CNV. A total of 56 patients were enrolled consecutively and randomised in a 1:1 ratio to receive combination treatment with intravitreal ranibizumab and topical ketorolac (group 1) or ranibizumab alone (group 2). All patients received monthly 0.5-mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered in accordance with the standard of care. Group 1 patients also self-administered one drop of ketorolac three times a day for 6 months. All patients were followed up for 6 months. Results: At 6 months, both groups showed a significant improvement in best-corrected visual acuity (both, p<0.001). The two treatments did not show significant differences in terms of the number of ranibizumab injections required. However, the mean 6-month change in central macular thickness (CMT) in the combination group was -124 μm (-29.7%; p<0.001), while in the ranibizumab-only group, the change was -86.9 μm (-19.5%; p=0.001); thus, the combination treatment resulted in a greater reduction (p=0.003). The combination treatment had no adverse effects. Conclusions: This pilot study is the first to prospectively investigate the efficacy and safety of a combination of 0.45% ketorolac eyedrops three times a day and intravitreal ranibizumab injections in patients with CNV, and suggests that topical ketorolac supplements the activity of intravitreal ranibizumab in reducing CMT in CNV. Source


Hengerer F.H.,Ruhr University Bochum | Dick H.B.,Ruhr University Bochum | Buchwald S.,Ruhr University Bochum | Hutz W.W.,Eye Clinic | Conrad-Hengerer I.,Ruhr University Bochum
Journal of Cataract and Refractive Surgery | Year: 2011

Purpose: To determine quantitative changes in endothelial cell loss and corneal thickness in patients having cataract surgery and implantation of a light-adjustable intraocular lens (IOL) to correct residual postoperative refractive errors by application of a spatially profiled near-ultraviolet (UV) light. Setting: Ruhr University Eye Clinic, Bochum, Germany. Design: Cohort study. Methods: The light-adjustable IOLs were implanted after phacoemulsification cataract surgery and treated with spatial-intensity-profiled UV light at 365 nm to induce a targeted refractive change. Once the desired correction was achieved, the light-adjustable IOL was treated again to lock-in the lens power. Noncontact computer-assisted endothelial cell microscopy and corneal pachymetry were performed before surgery; after surgery before adjustment; before lock-in; and 1, 3, 6, and 12 months after final lock-in. Results: One hundred twenty-two eyes were evaluated 12 months after lock-in. The mean cumulative UV light dose at the cornea was 61.47 J/cm 2 ± 2.37 (SD). The mean endothelial cell loss was 6.91% ± 3.66% 2 weeks after surgery before adjustment and 6.57% ± 3.81% 12 months after lock-in. The mean relative change in corneal thickness from preoperatively was 6.18% ± 3.97% 2 weeks postoperatively and -0.64% ± 1.88% 12 months after lock-in. Conclusions: Endothelial cell loss and corneal thickness change 12 months after lock-in agreed well with those reported in the literature after phacoemulsification with IOL implantation. The UV light exposure for adjustment and lock-in procedures did not add to the endothelial damage caused by the cataract surgery. Financial Disclosure: No author has a financial or proprietary interest in any material or method mentioned. © 2011 ASCRS and ESCRS. Source


Buch H.,Eye and Strabismus Clinic | Vinding T.,Eye Clinic
Acta Ophthalmologica | Year: 2015

Purpose To identify characteristics of pediatric patients who develop acute acquired comitant esotropia (AACE) with and without intracranial disease. Methods We reviewed the charts of 48 children consecutively referred to the hospital with AACE during a 13-year period. Inclusion criteria were acute onset of comitant esotropia, available data on ophthalmologic, orthoptic and neurologic examinations. Children with neurological signs, AACE recurrence or hyperopia <+3 dioptres (D) underwent brain computed tomography or magnetic resonance imaging. Patients without imaging were followed. Results In all, 48 cases were recorded. The mean age at onset was 4.7 years, being significantly higher among children with intracranial disease. Seven cause-specific types of AACE in childhood were identified: The acute accommodative (n = 15, 31%), decompensated monofixation syndrome or esophoria (n = 13, 27%), idiopathic (n = 9, 19%), intracranial disease (n = 3, 6%), occlusion related (n = 3, 6%), AACE secondary to different aetiologic disease (n = 3, 6%) and cyclic AACE (n = 2, 4%). Intracranial disease included hydrocephalus, pontine and thalamic glioma. Of the children with intracranial disease, 2 of 3 had no obvious neurological signs at onset. Four significant risk factors for intracranial disease were identified as follows: larger esodeviation at distance, recurrence of AACE, neuro signs (papilledema) and older age at onset (>6 years). Conclusion In a large case series of children with AACE and by review of literature, we identified seven cause-specific types of AACE. Intracranial disease was present in 6%, and four risk factors were identified to guide clinicians when to perform brain imaging. Findings suggest AACE of childhood to be differentiated from AACE of adulthood. © 2015 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd. Source


Goktas A.,Training and Research Hospital | Goktas S.,Eye Clinic
International Ophthalmology | Year: 2011

Acute depigmentation of the iris is a new condition characterized by pigment dispersion in the anterior chamber, depigmentation of the iris stroma, and pigment deposition in the anterior chamber angle. A 33-year-old woman using a topical corticosteroid every 2 h for the treatment of acute iridocyclitis was referred to our clinic to seek another opinion because her symptoms had not improved. An ocular evaluation of the patient revealed pigment precipitates on the corneal endothelium, pigment dispersion in the anterior chamber, symmetrical diffuse depigmentation, granularity of the iris stroma, and pigment deposition in the trabecular meshwork. These findings suggested a diagnosis of bilateral acute depigmentation of the iris (BADI) instead of iridocyclitis. Clinicians should be careful in the differential diagnosis of iris depigmentation from iridocyclitis to avoid the unnecessary use of high-dose topical corticosteroids. © 2011 Springer Science+Business Media B.V. Source

Discover hidden collaborations